Skip to main content
TipRanks
Go Ultimate75% OFF

Elite Pharmaceuticals (ELTP) AI Stock Analysis

378 Followers
ELTP

Elite Pharmaceuticals

(Other OTC:ELTP)

Select Model
Rating:68Neutral
Price Target:$0.40▲(9.02% Upside)
Action:downgraded
Date:11/17/26

The overall score of 68 reflects a company with strong fundamentals and a promising future that is currently facing significant technical headwinds. The most impactful factors are the company's explosive revenue growth, fortress-like balance sheet, and an ambitious pipeline, which are weighed against extremely overbought technical conditions that signal high near-term risk. The deeply undervalued P/E ratio and optimistic earnings call guidance provide further support, but the technicals are the primary drag on the score.

Positive Factors
Revenue growth and diversificationRevenue growth is supported by multiple product lines rather than a single legacy driver, improving the company’s business resilience. Broader contributions from amphetamine, opioid-addiction, and noncontrolled products can reduce concentration risk and provide a stronger base for sustained expansion.
Negative Factors
Weak and volatile cash conversionCash generation has not consistently matched reported earnings, which reduces confidence in the durability and quality of current profitability. Lower operating cash flow and weaker free cash flow can constrain internally funded investment, especially while Elite pursues product development and facility expansion.

Elite Pharmaceuticals (ELTP) vs. SPDR S&P 500 ETF (SPY)

-80%-60%-40%-20%0%20%ELTP-36.90%SPY+13.31%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$398.54M
Dividend Yield
―
Average Volume (3M)
816.47K
Price to Earnings (P/E)
6.5
Beta (1Y)
1.43
Revenue Growth
17.81%
EPS Growth
331.54%
Country
US
Employees
65
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Elite Pharmaceuticals Business Overview & Revenue Model

Company Description

Elite Pharmaceuticals, Inc. (ELTP) is a specialized pharmaceutical company focused on the creation and manufacturing of generic medications, as well as oral, controlled-release drug formulations. Its business activities are primarily divided into two...

Elite Pharmaceuticals Earnings Call Summary

Earnings Call Date:Nov 12, 2026(Q2-2027)|% Change Since:49.39%|Next Earnings Date:Aug 14, 2024
Earnings Call SentimentPositive

The call was predominantly optimistic, supported by 10% revenue growth, higher gross profit and margin year over year, stronger cash and working capital, a 34% reduction in liabilities, a more diversified revenue base, and a broad 2027-2028 R&D and facility expansion plan. The company also reiterated its NASDAQ objective. Offsetting concerns included lower operating cash flow, gross margin below the prior year, Lisdex quota constraints, outstanding internal-control remediation, pending NASDAQ and facility steps, potential warrant dilution, and unresolved FDA and legal matters. Highlights significantly outweighed the lowlights.

Positive Updates

Revenue Returned to Approximately $40 Million with More Diverse Drivers
Quarterly revenue was $40.1 million, compared with $36.3 million in the September 2025 quarter, an increase of $3.8 million or 10%. Growth was mostly driven by the amphetamine and opioid addiction treatment product lines, combined with increased Lisdex volumes and a stabilizing Lisdex market. Management said the revenue profile is now more diverse and no longer driven primarily by Lisdex.

Negative Updates

Operating Cash Flow Declined Year Over Year
Cash provided by operations for the six months ended September 2026 was $7 million, compared with $19.9 million for the six months ended September 2025. Management attributed the decrease to the prior year's stronger Lisdex margins before the generic-market correction and stabilization.

Company Guidance

Management said legacy products are steady, recently launched products “are expected to grow,” and the ADHD product line will grow, with “a BE study in 2027” possible. Elite expects approvable status for an undisclosed anticoagulant in 2027 and expects to launch it in 2028; another anticoagulant’s BE study is expected to begin “during the first half of 2027” and, “barring the unexpected an approval in 2028.” Management said it will conduct its first diabetes-product BE study “in the first half of 2027,” with a personal prediction of “2 to 3 BE studies” in 2027 but a commitment to one, and expects to file the anticonvulsant ANDA in “Q1 of 2027.” Elite expects to lease the remaining building in 2027, increasing GMP space from 85,000 square feet to 130,000 square feet, with a “serious expansion in 2027,” and said the first commercial batch may come in 2028. The company intends to apply for NASDAQ “sometime in Q1 of calendar 2027” and management expects to be listed “by March 2027,” “barring the unexpected”; internal-controls documentation and testing are expected to be in place by “April 2027.”

Elite Pharmaceuticals Financial Statement Overview

Summary

Financial performance is strong, driven by explosive revenue growth and a remarkable turnaround to profitability. The balance sheet is a fortress with minimal debt and high returns. However, the score is tempered by a contraction in gross margins and a sharp, 50.3% decline in free cash flow from prior peak levels, introducing uncertainty about the sustainability of current earnings quality.

Income Statement

78Positive

Balance Sheet

85Very Positive

Cash Flow

65Positive
Financial statement breakdown
BreakdownTTMMar 2026Jun 2025Jun 2024Mar 2023Mar 2022
Income Statement
Total Revenue144.77M148.87M84.04M56.63M34.16M32.26M
Gross Profit62.85M73.48M40.09M26.36M16.59M14.80M
EBITDA39.50M51.98M2.84M2.52M6.44M6.51M
Net Income60.28M44.87M-4.31M20.11M4.41M8.90M
Balance Sheet
Total Assets144.29M138.29M96.39M83.65M40.90M35.15M
Cash, Cash Equivalents and Short-Term Investments34.86M29.80B11.32M7.11M7.83M8.54M
Total Debt5.18M5.82M10.91M11.74M3.89M2.78M
Total Liabilities22.12M39.41M42.87M26.07M11.94M9.93M
Stockholders Equity122.17M98.88M53.52M57.58M28.96M25.22M
Cash Flow
Free Cash Flow8.72M22.82B4.93M-4.09M-2.40M6.01M
Operating Cash Flow10.86M23.75B7.46M-3.28M3.34M6.51M
Investing Cash Flow-2.15M-925.63M-2.40M-809.65K-5.74M-498.57K
Financing Cash Flow-456.11K-4.32B-825.74K3.39M1.70M-667.13K

Elite Pharmaceuticals Technical Analysis

Technical Analysis SentimentPositive
Last Price0.37

Price Trends

50DMA0.25Positive
100DMA0.30Positive
200DMA0.34Positive

Market Momentum

MACD0.01Negative
RSI85.98Negative
STOCH83.77Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ELTP, the sentiment is Positive. The current price of 0.37 is above the 20-day moving average (MA) of 0.25, above the 50-day MA of 0.25, and above the 200-day MA of 0.34, indicating a bullish trend. The MACD of 0.01 indicates Negative momentum. The RSI at 85.98 is Negative, neither overbought nor oversold. The STOCH value of 83.77 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ELTP.

Elite Pharmaceuticals Risk Analysis

Elite Pharmaceuticals disclosed 40 risk factors in its most recent earnings report. Elite Pharmaceuticals reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.While we currently qualify as a smaller reporting company under SEC regulations, we cannot be certain, if we take advantage of the reduced disclosure requirements applicable to these companies, that we will not make our stock less attractive to investors. Once we lose smaller reporting company status, the costs and demands placed upon our management are expected to increase.Q1, 2025
2.We most likely will require additional financing to meet our business objectives.Q1, 2025
3.Our ability to fund operations is uncertain and we may require additional financing to meet objectives.Q1, 2025

Elite Pharmaceuticals Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

ELTP against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
ETONETON79Outperform$1.84B36.09104.82%―100.61%―
ANIPANIP72Outperform$1.61B13.6320.00%―25.94%203.25%
ELTPELTP68Neutral$394.39M6.5259.37%―17.81%331.54%
AMRXAMRX58Neutral$7.40B49.43131.71%―8.88%2272.07%
CPIXCPIX53Neutral$78.13M1.18202.58%26.60%-39.11%-241.27%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
AQSTAQST47Neutral$472.59M-5.88255.11%―12.54%8.82%

* Healthcare Sector Average

Performance Comparison

0%200%400%ELTPANIPCPIXAMRXAQSTETONDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
ELTP and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
ELTPElite Pharmaceuticals0.37-0.19-34.64%
ANIPAni Pharmaceuticals70.89-10.18-12.56%
CPIXCumberland Pharmaceuticals Inc.5.213.68241.19%
AMRXAmneal Pharma21.239.6683.49%
AQSTAquestive Therapeutics, Inc.3.76-2.15-36.38%
ETONEton Pharmaceuticals63.8846.68271.40%

Elite Pharmaceuticals Corporate Events

Financial Disclosures

Elite Pharmaceuticals Reports Strong Fiscal 2027 Second-Quarter Results

Positive
Nov 12, 2026

On November 12, 2026, Elite Pharmaceuticals reported fiscal 2027 second-quarter results for the three months ended September 30, 2026. Revenue was $40.1 million, up $3.8 million, or approximately 10.4%, from the prior-year period; income from operati...

Financial Disclosures

Elite Pharmaceuticals Announces Upcoming Fiscal Second-Quarter Results

Neutral
Nov 12, 2026

On November 10, 2026, Elite Pharmaceuticals announced that it would release financial results for the second quarter of fiscal 2027 on November 12; the quarter ended September 30, 2026. Management was scheduled to host a live conference call on Novem...

Executive/Board Changes

Elite Pharmaceuticals Expands Board With Two New Directors

Positive
Nov 3, 2026

On October 28, 2026, Elite’s board increased its size from four to six directors and unanimously elected Aqeel A. Fatmi, Ph.D., as a Class II director and John W. LaRocca, Esq., as a Class I director. The company announced the appointments on Novembe...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 17, 2026